Augmenta Bioworks

Augmenta Bioworks, founded in 2021 and based in San Francisco, is a private, pre-clinical stage biotech leveraging synthetic biology to decode the human immune system. The company's core technology, DeepGrid™, combines advanced automation, microfluidics, high-throughput sequencing, and computational analysis to pinpoint rare, protective immune cells from which novel therapeutics can be derived. Augmenta operates a platform-plus-partnership business model, collaborating with pharmaceutical and biotech companies to discover antibodies, cell therapies, and immune modulators, positioning itself at the intersection of biologics discovery and personalized immunology.

DeepGrid™ platform integrating advanced automation, microfluidics, high-throughput DNA sequencing, and computational analysis to identify protective immune receptors and their antigen specificity from single human immune cells.

Augmenta competes with a range of companies, including established antibody discovery service providers (e.g., AbCellera, Distributed Bio), single-cell genomics platforms (10x Genomics, Berkeley Lights), and numerous startups in computational immunology and TCR discovery. Differentiation hinges on the integrated specificity mapping of the DeepGrid™ platform.